Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease.

PubWeight™: 1.75‹?› | Rank: Top 3%

🔗 View Article (PMC 1727949)

Published in Gut on July 01, 2000

Authors

R B Heuschkel1, T T MacDonald, G Monteleone, M Bajaj-Elliott, J A Smith, S L Pender

Author Affiliations

1: Department of Pediatric Gastroenterology, Royal Free and University College Medical School, London, UK.

Associated clinical trials:

Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis | NCT00265772

Articles citing this

Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut (2002) 1.65

Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol (2003) 1.51

Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut (2006) 1.47

Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut (2002) 1.41

Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol (2015) 1.34

Immunoregulation in the gut: success and failures in human disease. Gut (2002) 1.25

Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation. Gut (2002) 1.25

Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut (2004) 1.21

Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J Gastroenterol (2006) 1.16

Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol (2012) 1.07

Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity. World J Gastroenterol (2003) 1.02

Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut (2002) 1.00

The distinct roles of MMP-2 and MMP-9 in acute DSS colitis. Eur J Microbiol Immunol (Bp) (2011) 0.93

The impact of serine protease HtrA in apoptosis, intestinal immune responses and extra-intestinal histopathology during Campylobacter jejuni infection of infant mice. Gut Pathog (2014) 0.91

MMPs in the gut: inflammation hits the matrix. Gut (2000) 0.90

Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis (2009) 0.89

Lipid alterations in experimental murine colitis: role of ceramide and imipramine for matrix metalloproteinase-1 expression. PLoS One (2009) 0.88

Expression of matrix metalloproteinase-1 and tumor necrosis factor-alpha in ulcerative colitis. World J Gastroenterol (2007) 0.86

Expression of matrix metalloproteinases and tissue inhibitor metalloproteinases increases in X-irradiated rat ileum despite the disappearance of CD8a T cells. World J Gastroenterol (2005) 0.86

Selective gelatinase blockage ameliorates acute DSS colitis. Eur J Microbiol Immunol (Bp) (2011) 0.86

Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clin Exp Immunol (2009) 0.86

The effect of inositol hexaphosphate on the expression of selected metalloproteinases and their tissue inhibitors in IL-1β-stimulated colon cancer cells. Int J Colorectal Dis (2012) 0.85

Increased protein expression of matrix metalloproteinases -1, -3, and -9 and TIMP-1 in patients with gluten-sensitive enteropathy. Dig Dis Sci (2006) 0.84

Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation. Front Immunol (2015) 0.81

Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis. Mucosal Immunol (2014) 0.81

Protective effect of ilomastat on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. World J Gastroenterol (2008) 0.80

A place for TACE. Gut (2002) 0.79

Increased activity and expression of gelatinases in ischemic colitis. Dig Dis Sci (2006) 0.78

Matrix metalloproteinases in the restorative proctocolectomy pouch of pediatric ulcerative colitis. World J Gastroenterol (2012) 0.78

The synthetic hydroxyproline-containing collagen analogue (Gly-Pro-Hyp)10 ameliorates acute DSS colitis. Eur J Microbiol Immunol (Bp) (2012) 0.75

Fistulising Crohn's disease: MMPs gone awry. Gut (2004) 0.75

Novel Biomarkers and the Future Potential of Biomarkers in Inflammatory Bowel Disease. Mediators Inflamm (2017) 0.75

Basement membrane components. J Clin Pathol (2003) 0.75

Articles cited by this

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 10.67

Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J (1991) 8.29

Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut (1989) 4.59

Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr (1991) 4.11

Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol (1997) 4.09

Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut (1993) 3.25

Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology (1992) 3.04

Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem (1989) 2.87

A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol (1997) 2.13

Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem J (1977) 2.07

Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology (1999) 1.88

Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol (1996) 1.72

Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol (1994) 1.60

Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol (1997) 1.57

A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol (1998) 1.53

Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br J Dermatol (1996) 1.44

Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein (1996) 1.42

Enhancing Lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology (1999) 1.41

Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol (1998) 1.38

Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett (1997) 1.36

Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res (1994) 1.30

Suppression of T cell-mediated injury in human gut by interleukin 10: role of matrix metalloproteinases. Gastroenterology (1998) 1.14

Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. J Immunol (1993) 1.14

Metalloproteinase inhibitors and wound healing: a novel enhancer of wound strength. Surgery (1998) 1.07

Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts. Am J Pathol (1997) 1.06

Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum (1995) 1.06

Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr Eye Res (1996) 1.04

The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn's disease. Aliment Pharmacol Ther (1995) 1.03

TIMP expression in toxic and cholestatic liver injury in rat. J Hepatol (1997) 1.02

Clinical evaluation of serum tissue inhibitor of metalloproteinases-1 levels in patients with liver diseases. J Gastroenterol Hepatol (1993) 0.98

A new synthetic inhibitor of mammalian tissue collagenase inhibits bone resorption in culture. Biochem Biophys Res Commun (1985) 0.97

Proteolytic degradation of intestinal mucosal extracellular matrix after lamina propria T cell activation. Gut (1996) 0.96

TIMP-1 protein expression is stimulated by IL-1 beta and IL-6 in primary rat hepatocytes. FEBS Lett (1994) 0.92

Competitive RNA templates for detection and quantitation of growth factors, cytokines, extracellular matrix components and matrix metalloproteinases by RT-PCR. Biotechniques (1996) 0.92

Matrix metalloproteinases and endometrial remodelling. Cell Biol Int (1994) 0.91

Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr (1996) 0.87

Activation of extracellular matrix metalloproteases by proteases and organomercurials. Matrix Suppl (1992) 0.82

Phenotype of cells expressing matrix metalloproteinase-3 in ulcerative colitis. Ann N Y Acad Sci (1998) 0.78

Articles by these authors

Identification of a putative second T-cell receptor. Nature (1986) 7.90

Synthesis and crystal spacings of certain long-chain paraffins, ketones and secondary alcohols. Biochem J (1931) 7.19

Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet (1992) 6.66

The wax constituents of the apple cuticle. Biochem J (1931) 5.86

Do cells cycle? Proc Natl Acad Sci U S A (1973) 5.20

Urea as a partial protein substitute in the feeding of dairy cattle. Biochem J (1943) 4.72

The utilization of urea in the bovine rumen. 1. Methods of analysis of the rumen ingesta and preliminary experiments in vivo. Biochem J (1943) 4.17

Turns in peptides and proteins. Adv Protein Chem (1985) 4.05

The utilization of urea in the bovine rumen. 3. The synthesis and breakdown of protein in rumen ingesta. Biochem J (1943) 3.99

Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 3.63

High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. Proc Natl Acad Sci U S A (1989) 3.45

Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut (1993) 3.25

Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology (1993) 3.20

The dietary prevention of fatty livers. Triethyl-beta-hydroxyethylammonium hydroxide. Biochem J (1936) 3.13

The problem of appraising qualitative research. Qual Saf Health Care (2004) 3.12

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut (1991) 2.98

Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology (1994) 2.85

Expression of disulfide-linked and non-disulfide-linked forms of the T cell receptor gamma/delta heterodimer in human intestinal intraepithelial lymphocytes. Eur J Immunol (1989) 2.80

The relationship between early age of onset of initial substance use and engaging in multiple health risk behaviors among young adolescents. Arch Pediatr Adolesc Med (1999) 2.80

Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA (1996) 2.74

Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest (2001) 2.73

Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A (1989) 2.73

The fatty acids of pig liver: The octadecenoic acids and the desaturation theory. Biochem J (1934) 2.70

Lung volume reduction surgery for emphysema. Med J Aust (1997) 2.70

Personal performance profiles: a useful adjunct to quality assurance in cervical cytology. Cytopathology (1998) 2.65

Cell-mediated immunity to intestinal infection. Infect Immun (1980) 2.65

Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol (2001) 2.60

Immunological self, nonself discrimination. Science (1987) 2.59

Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc Natl Acad Sci U S A (1986) 2.55

Interferon gamma and interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut (1995) 2.52

Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease. Infect Immun (1999) 2.50

Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor. Science (1989) 2.48

Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut (2009) 2.48

Deposition of fat in the liver and carcass of the rat on diets high in fat and low in lipotropic factors. Biochem J (1937) 2.45

Training in large bowel cancer surgery: observations from three prospective regional United Kingdom audits. BMJ (1999) 2.44

Evaluating stat testing options in an academic health center: therapeutic turnaround time and staff satisfaction. Clin Chem (1998) 2.42

Cell-mediated immunity to gliadin within the small-intestinal mucosa in coeliac disease. Lancet (1975) 2.41

Sex differences and predictors of objective cough frequency in chronic cough. Thorax (2009) 2.41

Lumbar motion segment pathology adjacent to thoracolumbar, lumbar, and lumbosacral fusions. Spine (Phila Pa 1976) (1996) 2.38

ERS guidelines on the assessment of cough. Eur Respir J (2007) 2.36

Interaction of peptide antigens and class II major histocompatibility complex antigens. Nature (1987) 2.34

Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br J Pharmacol (1987) 2.30

Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med (1987) 2.28

Acute biomechanical and histological effects of intradiscal electrothermal therapy on human lumbar discs. Spine (Phila Pa 1976) (2001) 2.22

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol (1998) 2.16

Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains). Proc Natl Acad Sci U S A (1986) 2.13

A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol (1997) 2.13

Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA (1991) 2.12

Tissue characterization using magnetic resonance elastography: preliminary results. Phys Med Biol (2000) 2.11

Do pregnant women take their iron? Lancet (1969) 2.10

Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis. Gut (1990) 2.09

The detection of five antigenically reactive regions in the soybean leghemoglobin a molecule. Immunochemistry (1978) 2.09

Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion (2000) 2.09

Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa. J Immunol (2000) 2.08

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med (1991) 2.07

Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol (1999) 2.03

A clinical study of the Ahmed glaucoma valve implant in advanced glaucoma. Ophthalmology (1998) 2.03

Density-dependent variation in lifetime breeding success and natural and sexual selection in Soay rams. Am Nat (1999) 2.01

The endoscopic appearance of duodenal folds is predictive of untreated adult celiac disease. Gastrointest Endosc (1992) 2.01

Successful prophylaxis against febrile convulsions with valproic acid or phenobarbitone. Br Med J (1980) 2.01

Areal spread of the effect of cloud seeding at the whitetop experiment. Science (1969) 2.01

Hypersensitivity reactions in the small intestine. III. The effects of allograft rejection and of graft-versus-host disease on epithelial cell kinetics. Cell Tissue Kinet (1977) 2.00

Evaluation of the E test by using selected gram-positive bacteria. J Clin Microbiol (1992) 2.00

Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut (2007) 1.98

Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol (1993) 1.96

Enteroaggregative Escherichia coli expresses a novel flagellin that causes IL-8 release from intestinal epithelial cells. J Clin Invest (2000) 1.96

Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med (1988) 1.92

Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut (2002) 1.92

Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol (2001) 1.92

The fatty acids of pig liver: A general analysis. Biochem J (1935) 1.91

Fistula and sinus formation in xanthogranulomatous pyelonephritis. A clinicopathological review and report of four cases. Br J Urol (1986) 1.91

The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res (2005) 1.89

Xenorhabdus luminescens (DNA hybridization group 5) from human clinical specimens. J Clin Microbiol (1989) 1.88

High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet (1992) 1.88

Wind directions aloft and effects of seeding on precipitation in the whitetop experiment. Proc Natl Acad Sci U S A (1969) 1.88

Male reproductive success in a promiscuous mammal: behavioural estimates compared with genetic paternity. Mol Ecol (1999) 1.87

Increased acid-sensing ion channel ASIC-3 in inflamed human intestine. Eur J Gastroenterol Hepatol (2001) 1.87

The maintenance of genetic polymorphism in small island populations: large mammals in the Hebrides. Philos Trans R Soc Lond B Biol Sci (1996) 1.85

Continuous quality improvement for point-of-care testing using background monitoring of duplicate specimens. Arch Pathol Lab Med (1999) 1.85

Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease. Gut (2002) 1.82

Herbicide-resistant alfalfa cells: an example of gene amplification in plants. J Mol Appl Genet (1984) 1.82

The fatty acids of pig liver: Further evidence on the octadecenoic acids and the desaturation theory. Biochem J (1934) 1.82

Identification of a partial cDNA clone for the human receptor for complement fragments C3b/C4b. Proc Natl Acad Sci U S A (1985) 1.81

Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene (2010) 1.80

Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep (1984) 1.77

Expression of proinflammatory and Th1 but not Th2 cytokines is enhanced in gastric mucosa of Helicobacter pylori infected children. Dig Liver Dis (2001) 1.77

Streptococcus iniae, a human and animal pathogen: specific identification by the chaperonin 60 gene identification method. J Clin Microbiol (1998) 1.75

Neural substrates of fluid reasoning: an fMRI study of neocortical activation during performance of the Raven's Progressive Matrices Test. Cogn Psychol (1997) 1.74

Role of bacterial intimin in colonic hyperplasia and inflammation. Science (1999) 1.71

Focused microbiological surveillance and gram-negative beta-lactamase--mediated resistance in an intensive care unit. Infect Control Hosp Epidemiol (1995) 1.71

Dissemination of Bacillus cereus in an intensive care unit. Infect Control Hosp Epidemiol (1993) 1.70

Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut (1999) 1.70

Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol (2000) 1.69

Timing of the apparent effects of cloud seeding. Science (1969) 1.67

Clinical and economic outcomes of individuals with severe peptic ulcer hemorrhage and nonbleeding visible vessel: an analysis of two prospective clinical trials. Am J Gastroenterol (1998) 1.66